MRC Technology Archives

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […]

September 28, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 15 Jun 2017

MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences

LifeArc will draw funds from royalties of MSD’s successful checkpoint inhibitor Keytruda to invest in life sciences in both academic and business sectors. Born from the UK’s Medical Research Council, MRC Technology is a charity focused on supporting medical scientific research. Today, it becomes LifeArc and starts an ambitious new plan to invest up to […]

June 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma. After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This […]

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

stevenage biosciences catalyst catapult appolo MRC biotech

News and Trends 19 Apr 2016

Drug Discovery moves to Stevenage – the new Golden Triangle hotspot?

MRC Technology, a UK medical research charity, has moved most of its labs to the Stevenage Bioscience Catalyst (SBC) campus. Located inside the gold triangle, is this the new hotspot of UK Biotech? MRC Technology provides drug discovery services, as well as advice for commercialisation and intellectual property management, for academia and industry. Since it was founded […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 12 Jun 2015

MRC Technology and Peptinnovate partnered to cure bone diseases

MRC Technology and Peptinnovate teamed up to target bone diseases using peptides derived from the bacterium Mycobacterium tuberculosis. The partnership was created at Stevenage Bioscience Catalyst, a UK-based life sciences cluster. Natural peptides from M. tuberculosis, the pathogen that causes this feared disease, are able to modify the immunological and inflammatory response in humans. The bacteria employ […]

June 12, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us